Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Rank in Stocks #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Share Price
$1.69
Market Cap
$216.83M
Change (1 day)
3.38%
Change (1 year)
-65.61%
Country
US
Trade Organogenesis Holdings Inc. (ORGO)

Category

Price of ORGO with the market cap of B
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
ORGO
$1.69
Market Capitalization of Organogenesis Holdings Inc.(ORGO)
Market Cap: $216.83M
As of September 2026 Organogenesis Holdings Inc. has a market cap of $216.83M. This makes Organogenesis Holdings Inc. the world's 17992nd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Organogenesis Holdings Inc. from 2017 to 2026
ORGO compared with Top 5 Most Popular stocks
Price of ORGO Asset B Mkt. of B Results
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$42,155.14 $216.83M
$5.424T +2,501,539.97%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$37,116.02 $216.83M
$4.776T +2,202,500.65%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$31,488.85 $216.83M
$4.052T +1,868,563.68%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$28,685.07 $216.83M
$3.691T +1,702,177.25%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$21,327.01 $216.83M
$2.744T +1,265,523.00%